Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Repaglinide

Function:
Tablets and this product can be used alone for patients with type 2 diabetes who cannot effectively control high blood sugar through diet and exercise. It can also be used in patients with type 2 diabetes who cannot effectively control hyperglycemia with metformin. It can be used in combination with metformin, but it cannot replace metformin. Nateglinide is not suitable for patients with type 2 diabetes who are unsatisfactory for treatment with sulfonylureas. Capsules are indicated for the treatment of mild to moderate type 2 diabetes that cannot be controlled with diet, exercise therapy, and alpha-glucosidase inhibitors.

Dosage:
The usual dosage of tablets is 120 mg before meals, which can be used alone or in combination with metformin. The dosage should be adjusted according to the results of regular HbA1c testing (the maximum recommended dosage is 180 mg three times a day). Because the main therapeutic effect of nateglinide is to reduce mealtime blood sugar (which is an important component of HbA1c), the therapeutic effect of nateglinide can also be monitored through blood sugar 1-2 hours after a meal. In clinical trials, nateglinide was usually taken before major meals: breakfast, lunch, and dinner. For patients whose HbA1c level is close to the treatment target at the beginning of treatment (i.e. HbA1c <7.5%), it can be used alone or in combination with metformin. Just take 60 mg of nateglinide before meals, and adjust the dose according to the effect of treatment. Dosage in Patients with Hepatic Impairment No dosage adjustment is required in patients with mild to moderate hepatic disease. Nateglinide should not be used in patients with severe liver disease because it has not been studied in patients with severe liver disease. Dosage in Patients with Renal Impairment No dosage adjustment is required in patients with mild to moderate renal impairment. Despite the 49% reduction in Cmax in dialysis patients, the bioavailability and half-life of nateglinide are relevant to health in diabetic patients with moderate to severe renal insufficiency (creatinine clearance 15 to 50 ml/min) and in patients requiring dialysis. The subjects were comparable. However, for drug safety considerations, the dose should be adjusted if low Cmax occurs. Dispersible tablets for oral administration. When using, add this product to an appropriate amount of water, stir to disperse the product and then take it. Usually adults take 60-120 mg three times a day, within 1-15 minutes before meals. It is recommended to start with a small dose and adjust the dose based on the results of regular HbAlc or blood glucose tests 1 to 2 hours after a meal. Dosage in Patients with Hepatic Impairment No dosage adjustment is required in patients with mild to moderate hepatic disease. In patients with type 2 diabetes with mild to moderate hepatic impairment, the bioavailability and half-life of nateglinide do not differ to a clinically meaningful degree compared with healthy subjects. Dosing in patients with severe liver disease has not been studied and nateglinide should be used with caution in patients with severe liver disease. Patients with Renal Impairment Dosage No dosage adjustment is required in patients with renal impairment. In diabetic patients with moderate to severe renal insufficiency (creatinine clearance 15~50 ml/min/1.73m2) and patients requiring dialysis, the bioavailability and half-life of nateglinide are not different from those in healthy people. to a clinically significant extent. Capsules are taken orally. Usually adults take 60-120mg each time, three times a day, within 1-15 minutes before meals. It is recommended to start with a small dose and adjust the dose based on regular HbAlc or blood glucose test results 1-2 hours after a meal. The dose can be gradually increased to 180mg each time. Drug contraindications: If you are allergic to this product, it is contraindicated during lactation. It is contraindicated during pregnancy. Related dosage forms: tablet

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.